Abstract: The present invention relates to a method for predicting clinical outcome for a subject diagnosed with colorectal cancer, skin cancer, head and neck cancer or lung cancer. It also relates to a method for predicting whether a subject has a predisposition to develop such cancers as well as to a method for aiding the staging of such cancers in a subject. The methods of the present invention apply to the biomarkers MYO5B and/or RAB8A and optionally in addition to RAB9A, RAB10, RAB11A, RAB25, CDC42, RAC and/or RhoA.

Abstract: The invention relates to [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives. These [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives of selected phenolics are new, have a solubility in water higher than that of their parent O-?-D-Glcp-(1?-phenolic derivatives and have useful applications in cosmetic, nutrition and pharmaceutical compositions, such as treating or preventing oxidative stress, a cancer, a cardiovascular disease, a bacterial infection, a viral infection, a fungal infection, a UV-induced erythema, an allergy, a metabolism disorder, diabetes, an obesity, a hormonal disorder, a bone disease, a pain, a brain disease, a mouth or teeth disease, an inflammatory or immune disorder.